1360599-01-4

Upstream product

• 6311-35-9 6-bromonicotinic acid 
• 699-03-6 N-methyl-4-bromobenzylamine 
• 442134-70-5 6-bromo-N-(4-fluoro-phenyl)-nicotinamide 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1360599-06-9 C₂₆H₂₉BFN₃O₃ 
• 1360598-89-5 SX-632 

Relevant academic research and scientific papers

Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability

Abstract The chemokine receptors CXCR1 and CXCR2 are important pharmaceutical targets due to their key roles in inflammatory diseases and cancer progression. We have previously identified 2-[5-(4-fluoro-phenylcarbamoyl)-pyridin-2-ylsulfanylmethyl]-phenylboronic acid (SX-517) and 6-(2-boronic acid-5-trifluoromethoxy-benzylsulfanyl)-N-(4-fluoro-phenyl)-nicotinamide (SX-576) as potent non-competitive boronic acid-containing CXCR1/2 antagonists. Herein we report the synthesis and evaluation of aminopyridine and aminopyrimidine analogs of SX-517 and SX-576, identifying (2-{(benzyl)[(5-boronic acid-2-pyridyl)methyl]amino}-5-pyrimidinyl)(4-fluorophenylamino)formaldehyde as a potent chemokine antagonist with improved aqueous solubility and oral bioavailability.

Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators

There is disclosed aminopyridine-and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, ther